- Home
- GDL vs JSPR Comparison
GDL vs JSPR Comparison
Compare GDL & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- JSPR
- Stock Information
- Founded
- GDL 2006
- JSPR 2018
- Country
- GDL United States
- JSPR United States
- Employees
- GDL N/A
- JSPR N/A
- Industry
- GDL Investment Managers
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDL Finance
- JSPR Health Care
- Exchange
- GDL Nasdaq
- JSPR Nasdaq
- Market Cap
- GDL 96.8M
- JSPR 82.4M
- IPO Year
- GDL N/A
- JSPR N/A
- Fundamental
- Price
- GDL $8.34
- JSPR $5.96
- Analyst Decision
- GDL
- JSPR Strong Buy
- Analyst Count
- GDL 0
- JSPR 12
- Target Price
- GDL N/A
- JSPR $64.44
- AVG Volume (30 Days)
- GDL 11.2K
- JSPR 452.6K
- Earning Date
- GDL 01-01-0001
- JSPR 03-07-2025
- Dividend Yield
- GDL 6.02%
- JSPR N/A
- EPS Growth
- GDL N/A
- JSPR N/A
- EPS
- GDL N/A
- JSPR N/A
- Revenue
- GDL N/A
- JSPR N/A
- Revenue This Year
- GDL N/A
- JSPR N/A
- Revenue Next Year
- GDL N/A
- JSPR N/A
- P/E Ratio
- GDL N/A
- JSPR N/A
- Revenue Growth
- GDL N/A
- JSPR N/A
- 52 Week Low
- GDL $7.65
- JSPR $4.55
- 52 Week High
- GDL $8.13
- JSPR $31.01
- Technical
- Relative Strength Index (RSI)
- GDL 66.71
- JSPR 34.64
- Support Level
- GDL $8.29
- JSPR $4.55
- Resistance Level
- GDL $8.37
- JSPR $6.55
- Average True Range (ATR)
- GDL 0.05
- JSPR 0.53
- MACD
- GDL 0.01
- JSPR 0.49
- Stochastic Oscillator
- GDL 82.61
- JSPR 56.18
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.